Navigation Links
OncoGenex Announces Update on Phase 3 SYNERGY Trial Evaluating Custirsen in Men with Metastatic Castrate-Resistant Prostate Cancer
Date:11/19/2013

BOTHELL, Wash. and VANCOUVER, British Columbia, Nov. 19, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that the SYNERGY trial is continuing as planned per the recommendation of the Independent Data Monitoring Committee (IDMC).

The primary registration Phase 3 SYNERGY trial is designed to evaluate a survival benefit for custirsen in combination with first-line docetaxel chemotherapy in men with metastatic castrate-resistant prostate cancer (CRPC). Approximately 1,023 men have been enrolled to SYNERGY at 140 sites primarily in North America and Europe. SYNERGY completed enrollment in 2012 and final survival results are expected to be announced by mid-2014.

"The recommendation for SYNERGY to continue to final analysis is not surprising as the criteria to achieve statistical significance on the interim are considerably more stringent than the criteria required for the final analysis," stated Scott Cormack, President and CEO of OncoGenex.  "We do not believe these results can be interpreted to predict the final outcome of SYNERGY and we eagerly anticipate the reporting of final survival results next year."

OncoGenex and custirsen co-development and commercialization partner, Teva Pharmaceutical Industries, Ltd., continue to remain blinded to all SYNERGY data and analyses, including details regarding survival and statistical evaluations. The IDMC also remains blinded to the details of the interim efficacy data and analyses.

ABOUT ONCOGENEX
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OncoGenex to Report Financial Results for Third Quarter 2013 and Address Key Questions from Investors on November 7, 2013
2. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for Second Quarter 2013
3. OncoGenex Announces Multiple Trials in Progress Presentations at the 2013 ASCO Annual Meeting
4. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
5. OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012
6. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
7. OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
8. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
9. Assured Pharmacy, Inc. Announces Extension of Issuer Tender Offer
10. Valeant Pharmaceuticals Announces Pricing Of Private Offering Of Senior Notes
11. International Isotopes Inc. Announces Third Quarter And Nine Months 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... TAIPEI , May 4, 2015 ... partner, Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) ... BAX ) jointly announced that Baxter has ... European Medicines Agency (EMA) for MM-398 (irinotecan liposome ... metastatic adenocarcinoma of the pancreas who have been ...
(Date:5/4/2015)... DOYLESTOWN, Pa. , May 4, 2015  Makindus, ... announced today that the European Medicines Agency (EMA) has ... for the treatment of Stargardt,s Disease. "We ... for MI-100 to treat Stargardt,s disease in place for ... our development program in the United States ...
(Date:5/4/2015)... Bayer HealthCare (Bayer) has entered into an ... ISIS ) on ISIS-FXI Rx, an antisense investigational ... Under the agreement Bayer will further develop and commercialize ... need. As part of the clinical development program, Bayer ... in an appropriate patient community. "Bayer ...
Breaking Medicine Technology:PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 2PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 3European Medicines Agency (EMA) Grants Orphan Designation for Makindus' MI-100 for Stargardt's Disease 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 3
... Delcath Systems, Inc. (Nasdaq: DCTH ) announced ... discuss its recent corporate developments and update its progress on ... President and Chief Executive Officer will host the call. ... 800-322-5044 for domestic participants and 617-614-4927 for international participants, both ...
... 2011 CVS Caremark Corporation (NYSE: CVS ... present at two investor conferences in the month of ... CVS Caremark, will be making a presentation to investors ... on Thursday, November 10th, at approximately 10:00 a.m. MST ...
Cached Medicine Technology:Delcath Systems to Report Third Quarter Progress and Conduct Conference Call 2Delcath Systems to Report Third Quarter Progress and Conduct Conference Call 3CVS Caremark to Present at Upcoming Conferences 2
(Date:5/4/2015)... Ticket Down is a reputable source for authentic ... in Charlottesville, VA. McCartney is one of the most ... this beloved performer continues to roll along with no signs ... legendary groups: Wings and The Beatles, has been celebrating his ... the “Out There” tour and has continually added new stops ...
(Date:5/4/2015)... New findings released today from a poll conducted ... people diagnosed with a brain tumor needed more information ... at the time of diagnosis, and had only a ... course of treatment. The release of these findings corresponds ... volunteer network, the ABTA CommYOUnity™, dedicated to serving the ...
(Date:5/4/2015)... Fork, UT (PRWEB) May 04, 2015 ... surgery (up to $3,000) of one patient receiving care at ... of Utah. The procedure must be performed by July ... (willing to pay in full up front and forego the ... U.S. becomes more economically burdensome every year, and it devastates ...
(Date:5/4/2015)... Sheltering Arms announced that it has ... The Mother Hale Learning Center meets a tremendous need ... Sheltering Arms will begin operating the site immediately and ... the center. , Opened in 2006, the Mother Hale ... five years, many of whom come from high-need backgrounds. ...
(Date:5/4/2015)... Helena, MT (PRWEB) May 04, 2015 ... partnered with Care to Care, LLC to manage outpatient ... will help New West Medicare ensure its members are ... avoid unnecessary radiation. , Working closely with New West ... in promoting the safe use of advanced imaging and ...
Breaking Medicine News(10 mins):Health News:Paul McCartney Tickets at John Paul Jones Arena in Charlottesville, VA: Ticket Down Slashes Paul McCartney Ticket Prices in Charlottesville at the John Paul Jones Arena 2Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 2Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 3Health News:Pricing Healthcare to Pay a Patient's Bill for a Procedure at Utah Facility 2Health News:Pricing Healthcare to Pay a Patient's Bill for a Procedure at Utah Facility 3Health News:Sheltering Arms Acquires the Mother Hale Learning Center 2Health News:New West Medicare Partners with Care to Care, LLC to Manage Advanced Imaging Services 2
... Mainstream Management ProcessSTUART, Fla., March 20 /PRNewswire/ ... community-based healthcare organization covering two counties in Florida, ... interests for its board of directors, committee members ... a moderately sized community, it was not uncommon ...
... the Migraine Research Foundation (MRF) announced a new initiative ... migraine called FOR OUR CHILDREN. The new program ... understanding of migraine and its causes and treatments in ... , Migraine is very common in children - ...
... and You Could Also Win a $25 Visa(R) Gift Card ... much calcium you need each day? Or which foods are ... answers to these and other nutrition questions, then pull up ... Take the Shedd,s Spread Country Crock (R) Calcium quiz ...
... Corporation (NYSE: HLS ) announced today that ... dividend of $16.25 per share on its 6.5% Series ... 2009, to holders of record on April 1, 2009. ... largest provider of inpatient rehabilitative healthcare services. Operating in ...
... techniques, the accuracy of preoperative rectal cancer staging has ... rectal cancer patients has become a very important aim ... published on March 14, 2009 in the World ... 5-year survival after local excision of rectal cancer, and ...
... University, together with colleagues at the Karolinska Institute and ... the determine the dosage of the blood-thinning drug warfarin. ... PLoS Genetics . , "We have previously studied selected ... have gone in and scanned the entire genome, we ...
Cached Medicine News:Health News:MediTract's Compliance Management Tools Improve Efficiencies at Martin Memorial Health Systems 2Health News:MediTract's Compliance Management Tools Improve Efficiencies at Martin Memorial Health Systems 3Health News:MediTract's Compliance Management Tools Improve Efficiencies at Martin Memorial Health Systems 4Health News:MediTract's Compliance Management Tools Improve Efficiencies at Martin Memorial Health Systems 5Health News:New initiative to support pediatric migraine research is announced 2Health News:Bone Up On Calcium and Vitamin D for a Chance to Win a Family Vacation to Yellowstone National Park 2Health News:Bone Up On Calcium and Vitamin D for a Chance to Win a Family Vacation to Yellowstone National Park 3
... proven electrophoretic transfer apparatus incorporating state-of-the-art plate ... Its design allows for a very close ... with a low voltage power source such ... field in volts/cm. The result is exceptionally ...
... RNA from agarose gels to hybridization membranes ... speed and efficiency of transfer by allowing ... ,Part of an integrated system allowing electrophoresis, ... 2.5 hours, versus 29 hours required for ...
... Transfers depurinated DNA and RNA from agarose ... as 15 minutes ,Increases speed and efficiency ... be applied to gel ,Part of an ... and UV crosslinking in 2.5 hours, versus ...
Ice block will provide sufficient cooling for most normal blotting applications. Sealed block is held submerged in transfer buffer. Ice block will not spill during refreezing....
Medicine Products: